Answers are grounded in this paper and cite their sources.
The clinical use of immune checkpoint inhibitors is expanding rapidly. Oncology practitioners will therefore be required to recognize and manage irAEs in a growing patient population. Early recognition and treatment are essential to prevent patient morbidity and mortality, and adherence to established algorithms is recommended.
No takes yet. Share an insight, caveat, or question.
Friedman et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: